ESCALON MEDICAL CORP
No SEC Form 4 filings for $ESMC in the last 30 days.
See all $ESMC insider activity →Escalon Medical Corp reported FY 2026 revenue of $12.74M, up 5.7% YoY, and net income of $4.01M, driven by Sonomed sales and a one-time gain from AXIS software sale. International sales rose to 46.4% of revenue. R&D spending declined 33.5%.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ESMC (ESCALON MEDICAL CORP). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
The surprise profit and revenue growth may lift the stock modestly.
AlphAI scores every news story that mentions ESMC with an AI model for sentiment and relevance, and aggregates insider trades from ESCALON MEDICAL CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Escalon Medical Corp reported FY 2026 revenue of $12.74M, up 5.7% YoY, and net income of $4.01M, driven by Sonomed sales and a one-time gain from AXIS software sale. International sales rose to 46.4% of revenue. R&D spending declined 33.5%.
1 min read
